VistaGen Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on March 22, 2016. The filing reports corporate governance updates regarding the expansion of the Company's Clinical and Regulatory Advisory Board.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the appointment of two new members to the Clinical and Regulatory Advisory Board:
- Thomas Laughren, M.D., former Division Director for the FDA's Division of Psychiatry Products.
- Sanjay Mathew, M.D., Associate Professor of Psychiatry and Behavioral Sciences at Baylor College of Medicine.
Additionally, existing board member Maurizio Fava, M.D., was appointed as Chairman of the Board.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document serves solely to disclose the advisory board changes and references an attached press release (Exhibit 99.1) for further details.
Key Facts for Investor Verification
- Verify the specific roles and responsibilities of the newly appointed advisory board members.
- Review the attached press release (Exhibit 99.1) for any additional strategic context regarding these appointments.
- Confirm the current composition of the Clinical and Regulatory Advisory Board including existing members Gerard Sanacora, M.D., Ph.D., and Maurizio Fava, M.D.